Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy

Hiddo J.L. Heerspink, Dennis L. Andress, George Bakris, John J. Brennan, Ricardo Correa-Rotter, Jyotirmoy Dey, Fan Fan Hou, Dalane W. Kitzman, Donald Kohan, Hirofumi Makino, John McMurray, Vlado Perkovic, Sheldon Tobe, Melissa Wigderson, Hans Henrik Parving, Dick de Zeeuw

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Aims: Individuals with diabetes and chronic kidney disease (CKD) are at high risk for renal events. Recent trials of novel treatments have been negative, possibly because of variability in response to treatment of the target risk factor. Atrasentan is a selective endothelin A receptor antagonist that reduces urinary albumin-to-creatinine ratio (UACR), with a large variability between patients. We are assessing its effect on renal outcomes in the Study Of diabetic Nephropathy with AtRasentan (SONAR; NCT01858532) with an enrichment design (>30% lowering of albuminuria) to select patients most likely to benefit. Materials and Methods: SONAR is a randomized, double-blind, placebo-controlled trial with approximately 3500 participants who have stage 2–4 CKD and macroalbuminuria and are receiving a maximum tolerated dose of a renin-angiotensin system inhibitor. Results: After 6 weeks of exposure to atrasentan 0.75 mg once daily (enrichment period), participants with ≥30% UACR decrease and no tolerability issues (responders) were randomly assigned to placebo or atrasentan 0.75 mg/day. The responder group will be used for primary efficacy and safety analyses. Approximately 1000 participants with <30% UACR reduction (non-responders) were also randomized to placebo or atrasentan. The primary endpoint is a composite of a sustained doubling of serum creatinine or end-stage renal disease. The original power calculation indicated that a total of 425 primary renal events in the responder group provides 90% power to detect a 27% reduction in relative risk (alpha level of.05). Conclusion: SONAR aims to determine whether atrasentan added to guideline-recommended therapies safely reduces the risk of CKD progression and delays the onset of end-stage renal disease in patients with type 2 diabetes and nephropathy. SONAR also aims to establish whether the enrichment of patients based on their initial “surrogate” response to atrasentan will deliver a trial design in accord with personalized treatment of diabetic kidney disease.

Original languageEnglish
Pages (from-to)1369-1376
Number of pages8
JournalDiabetes, Obesity and Metabolism
Volume20
Issue number6
DOIs
Publication statusPublished - Jun 1 2018

Fingerprint

Diabetic Nephropathies
Clinical Trials
Creatinine
Chronic Renal Insufficiency
Albumins
Placebos
Kidney
Chronic Kidney Failure
atrasentan
Albuminuria
Maximum Tolerated Dose
Therapeutics
Renin-Angiotensin System
Type 2 Diabetes Mellitus
Disease Progression
Outcome Assessment (Health Care)
Guidelines
Safety

Keywords

  • atrasentan
  • diabetic kidney disease
  • endothelin receptor antagonist
  • personalized medicine
  • randomized controlled clinical trial

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Heerspink, H. J. L., Andress, D. L., Bakris, G., Brennan, J. J., Correa-Rotter, R., Dey, J., ... de Zeeuw, D. (2018). Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. Diabetes, Obesity and Metabolism, 20(6), 1369-1376. https://doi.org/10.1111/dom.13245

Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial : A clinical trial design novel to diabetic nephropathy. / Heerspink, Hiddo J.L.; Andress, Dennis L.; Bakris, George; Brennan, John J.; Correa-Rotter, Ricardo; Dey, Jyotirmoy; Hou, Fan Fan; Kitzman, Dalane W.; Kohan, Donald; Makino, Hirofumi; McMurray, John; Perkovic, Vlado; Tobe, Sheldon; Wigderson, Melissa; Parving, Hans Henrik; de Zeeuw, Dick.

In: Diabetes, Obesity and Metabolism, Vol. 20, No. 6, 01.06.2018, p. 1369-1376.

Research output: Contribution to journalArticle

Heerspink, HJL, Andress, DL, Bakris, G, Brennan, JJ, Correa-Rotter, R, Dey, J, Hou, FF, Kitzman, DW, Kohan, D, Makino, H, McMurray, J, Perkovic, V, Tobe, S, Wigderson, M, Parving, HH & de Zeeuw, D 2018, 'Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy', Diabetes, Obesity and Metabolism, vol. 20, no. 6, pp. 1369-1376. https://doi.org/10.1111/dom.13245
Heerspink, Hiddo J.L. ; Andress, Dennis L. ; Bakris, George ; Brennan, John J. ; Correa-Rotter, Ricardo ; Dey, Jyotirmoy ; Hou, Fan Fan ; Kitzman, Dalane W. ; Kohan, Donald ; Makino, Hirofumi ; McMurray, John ; Perkovic, Vlado ; Tobe, Sheldon ; Wigderson, Melissa ; Parving, Hans Henrik ; de Zeeuw, Dick. / Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial : A clinical trial design novel to diabetic nephropathy. In: Diabetes, Obesity and Metabolism. 2018 ; Vol. 20, No. 6. pp. 1369-1376.
@article{9dfd9a5109e3422aaf594d233139a8d9,
title = "Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy",
abstract = "Aims: Individuals with diabetes and chronic kidney disease (CKD) are at high risk for renal events. Recent trials of novel treatments have been negative, possibly because of variability in response to treatment of the target risk factor. Atrasentan is a selective endothelin A receptor antagonist that reduces urinary albumin-to-creatinine ratio (UACR), with a large variability between patients. We are assessing its effect on renal outcomes in the Study Of diabetic Nephropathy with AtRasentan (SONAR; NCT01858532) with an enrichment design (>30{\%} lowering of albuminuria) to select patients most likely to benefit. Materials and Methods: SONAR is a randomized, double-blind, placebo-controlled trial with approximately 3500 participants who have stage 2–4 CKD and macroalbuminuria and are receiving a maximum tolerated dose of a renin-angiotensin system inhibitor. Results: After 6 weeks of exposure to atrasentan 0.75 mg once daily (enrichment period), participants with ≥30{\%} UACR decrease and no tolerability issues (responders) were randomly assigned to placebo or atrasentan 0.75 mg/day. The responder group will be used for primary efficacy and safety analyses. Approximately 1000 participants with <30{\%} UACR reduction (non-responders) were also randomized to placebo or atrasentan. The primary endpoint is a composite of a sustained doubling of serum creatinine or end-stage renal disease. The original power calculation indicated that a total of 425 primary renal events in the responder group provides 90{\%} power to detect a 27{\%} reduction in relative risk (alpha level of.05). Conclusion: SONAR aims to determine whether atrasentan added to guideline-recommended therapies safely reduces the risk of CKD progression and delays the onset of end-stage renal disease in patients with type 2 diabetes and nephropathy. SONAR also aims to establish whether the enrichment of patients based on their initial “surrogate” response to atrasentan will deliver a trial design in accord with personalized treatment of diabetic kidney disease.",
keywords = "atrasentan, diabetic kidney disease, endothelin receptor antagonist, personalized medicine, randomized controlled clinical trial",
author = "Heerspink, {Hiddo J.L.} and Andress, {Dennis L.} and George Bakris and Brennan, {John J.} and Ricardo Correa-Rotter and Jyotirmoy Dey and Hou, {Fan Fan} and Kitzman, {Dalane W.} and Donald Kohan and Hirofumi Makino and John McMurray and Vlado Perkovic and Sheldon Tobe and Melissa Wigderson and Parving, {Hans Henrik} and {de Zeeuw}, Dick",
year = "2018",
month = "6",
day = "1",
doi = "10.1111/dom.13245",
language = "English",
volume = "20",
pages = "1369--1376",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial

T2 - A clinical trial design novel to diabetic nephropathy

AU - Heerspink, Hiddo J.L.

AU - Andress, Dennis L.

AU - Bakris, George

AU - Brennan, John J.

AU - Correa-Rotter, Ricardo

AU - Dey, Jyotirmoy

AU - Hou, Fan Fan

AU - Kitzman, Dalane W.

AU - Kohan, Donald

AU - Makino, Hirofumi

AU - McMurray, John

AU - Perkovic, Vlado

AU - Tobe, Sheldon

AU - Wigderson, Melissa

AU - Parving, Hans Henrik

AU - de Zeeuw, Dick

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Aims: Individuals with diabetes and chronic kidney disease (CKD) are at high risk for renal events. Recent trials of novel treatments have been negative, possibly because of variability in response to treatment of the target risk factor. Atrasentan is a selective endothelin A receptor antagonist that reduces urinary albumin-to-creatinine ratio (UACR), with a large variability between patients. We are assessing its effect on renal outcomes in the Study Of diabetic Nephropathy with AtRasentan (SONAR; NCT01858532) with an enrichment design (>30% lowering of albuminuria) to select patients most likely to benefit. Materials and Methods: SONAR is a randomized, double-blind, placebo-controlled trial with approximately 3500 participants who have stage 2–4 CKD and macroalbuminuria and are receiving a maximum tolerated dose of a renin-angiotensin system inhibitor. Results: After 6 weeks of exposure to atrasentan 0.75 mg once daily (enrichment period), participants with ≥30% UACR decrease and no tolerability issues (responders) were randomly assigned to placebo or atrasentan 0.75 mg/day. The responder group will be used for primary efficacy and safety analyses. Approximately 1000 participants with <30% UACR reduction (non-responders) were also randomized to placebo or atrasentan. The primary endpoint is a composite of a sustained doubling of serum creatinine or end-stage renal disease. The original power calculation indicated that a total of 425 primary renal events in the responder group provides 90% power to detect a 27% reduction in relative risk (alpha level of.05). Conclusion: SONAR aims to determine whether atrasentan added to guideline-recommended therapies safely reduces the risk of CKD progression and delays the onset of end-stage renal disease in patients with type 2 diabetes and nephropathy. SONAR also aims to establish whether the enrichment of patients based on their initial “surrogate” response to atrasentan will deliver a trial design in accord with personalized treatment of diabetic kidney disease.

AB - Aims: Individuals with diabetes and chronic kidney disease (CKD) are at high risk for renal events. Recent trials of novel treatments have been negative, possibly because of variability in response to treatment of the target risk factor. Atrasentan is a selective endothelin A receptor antagonist that reduces urinary albumin-to-creatinine ratio (UACR), with a large variability between patients. We are assessing its effect on renal outcomes in the Study Of diabetic Nephropathy with AtRasentan (SONAR; NCT01858532) with an enrichment design (>30% lowering of albuminuria) to select patients most likely to benefit. Materials and Methods: SONAR is a randomized, double-blind, placebo-controlled trial with approximately 3500 participants who have stage 2–4 CKD and macroalbuminuria and are receiving a maximum tolerated dose of a renin-angiotensin system inhibitor. Results: After 6 weeks of exposure to atrasentan 0.75 mg once daily (enrichment period), participants with ≥30% UACR decrease and no tolerability issues (responders) were randomly assigned to placebo or atrasentan 0.75 mg/day. The responder group will be used for primary efficacy and safety analyses. Approximately 1000 participants with <30% UACR reduction (non-responders) were also randomized to placebo or atrasentan. The primary endpoint is a composite of a sustained doubling of serum creatinine or end-stage renal disease. The original power calculation indicated that a total of 425 primary renal events in the responder group provides 90% power to detect a 27% reduction in relative risk (alpha level of.05). Conclusion: SONAR aims to determine whether atrasentan added to guideline-recommended therapies safely reduces the risk of CKD progression and delays the onset of end-stage renal disease in patients with type 2 diabetes and nephropathy. SONAR also aims to establish whether the enrichment of patients based on their initial “surrogate” response to atrasentan will deliver a trial design in accord with personalized treatment of diabetic kidney disease.

KW - atrasentan

KW - diabetic kidney disease

KW - endothelin receptor antagonist

KW - personalized medicine

KW - randomized controlled clinical trial

UR - http://www.scopus.com/inward/record.url?scp=85043400847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043400847&partnerID=8YFLogxK

U2 - 10.1111/dom.13245

DO - 10.1111/dom.13245

M3 - Article

C2 - 29405626

AN - SCOPUS:85043400847

VL - 20

SP - 1369

EP - 1376

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 6

ER -